Year :

ASH 2018: Updated Data from Phase 1/2 Open-Label Study of BCMA-Directed CAR-T Cell Therapy LCAR-B38M Show Tolerable Safety Profile, High Overall Response and MRD Negative Rate in Treatment of Patients with Advanced Relapsed or Refractory Multiple Myeloma

San Diego, CA, December 3, 2018 – Legend Biotech reported updated data on the LEGEND-2 Phase 1/2 open label study, which evaluated the investigational chimeric antigen receptor T-cell (CAR-T) therapy LCAR-B38M in the treatment of patients with advanced relapsed or refractory (R/R) multiple myeloma. The findings, featured in an oral presentation at the 2018 American […]

Dec 03, 2018

Legend Biotech Chairman Frank Zhang awarded 2018 Person of the Year from China Healthcare Summit

Piscataway, NJ (November 14, 2018): China Healthcare Summit 2018 hosted by BioCentury and BayHelix announced Dr. Frank Zhang, GenScript’s founder, as the winner of its Person of the Year Award. The goal of this award was to recognize an outstanding individual whose contributions have changed the landscape, reputation, and ecosystem of drug and/or medical technology R&D, […]

Nov 14, 2018

Legend Announces FDA clearance of IND application on CAR-T immuno-cell therapy for the Treatment of Multiple Myeloma

LCAR-B38M CAR-T therapy (JNJ-68284528) to be developed as part of strategic partnership between Legend and Janssen.Piscataway, NJ (May 30, 2018) – Legend Biotech, a subsidiary of GenScript Biotech Corporation (HKEx: 1548), announced today that the U.S. Food and Drug Administration (FDA) has authorized its development partner, Janssen Biotech, Inc. (“Janssen”), to commence a Phase 1b/2 […]

May 30, 2018

Nanjing Legend formally received the permission of a clinical trial granted by the CFDA with respect to LCAR-B38M CAR-T for autologous infusion

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the […]

Mar 13, 2018

Legend Biotech Announces Closing of Global Strategic LCAR-B38M CAR-T Cell Immunotherapy Collaboration with Janssen

Legend to receive an upfront payment of $350 million, as well as additional development, production performance, regulatory and sales milestone payments Legend and Janssen to co-develop and co-promote CAR-T cell therapy for multiple myeloma Profits and costs to be shared 50/50 worldwide, exclusive Greater China where 70 percent to Legend and 30 percent to Janssen […]

Dec 22, 2017

Thank you for your interest in learning more about Legend Biotech.

Media Relations & Communications

media@legendbiotech.com

close

You are about to leave LegendBiotech.com

You are going to a website that Legend Biotech does not operate and to which Legend Biotech's privacy policy does not apply. Legend Biotech is not responsible for the content, format, maintenance or policies of the website you are about to visit and does not endorse or monitor any content on such website.

We use cookies to improve your experience on our website, measure performance, understand our audience, for advertising and support purposes. You can always change your preferences or opt out from our use of cookies.